Bone marrow transplantation for sickle cell disease

New England Journal of Medicine

Volumn 335, Issue 6, 1996, Pages 369-376

  Walters, Mark C ^a,b   Patience, Melinda ^a   Leisenring, Wendy ^a   Eckman, James R ^d   Scott, J Paul ^e   Mentzer, William C ^f   Davies, Sally C ^g   Ohene Frempong, Kwaku ^h   Bernaudin, Françoise ⁱ   Matthews, Dana C ^a,b   Storb, Rainer ^a,c   Sullivan, Keith M ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d EMORY UNIVERSITY   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g EALING HOSPITAL NHS TRUST   (United Kingdom)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; THYMOCYTE ANTIBODY;

ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; MALE; PRIORITY JOURNAL; SIBLING; SICKLE CELL ANEMIA; STEM CELL TRANSPLANTATION; SURVIVAL; TREATMENT INDICATION;

ADOLESCENT; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; BONE MARROW TRANSPLANTATION; CEREBRAL HEMORRHAGE; CEREBROVASCULAR DISORDERS; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 9344231922     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199608083350601     Document Type: Article

References (39)

1. Parkman R. The application of bone marrow transplantation to the treatment of genetic diseases. Science 1986;232:1373-8.
2. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990;322:417-21.
3. Camitta BM, Storb R, Thomas ED. Aplastic anemia: pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med 1982;306:645-52, 712-8.
4. Johnson FL, Look AT, Gockerman J, Ruggiero MR, Dalla Pozza L, Billings FT III. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med 1984;311:780-3.
5. Vermylen C, Robles EF, Ninane J, Cornu G. Bone marrow transplantation in five children with sickle cell anemia. Lancet 1988;1:1427-8.
6. Sullivan KM, Reid CD. Introduction to a symposium on sickle cell anemia: current results of comprehensive care and the evolving role of bone marrow transplantation. Semin Hematol 1991;28:177-9.
7. Ferster A, De Valck C, Azzi N, Fondu P, Toppet M, Sariban E. Bone marrow transplantation for severe sickle cell anaemia. Br J Haematol 1992; 80:102-5.
8. Johnson FL, Mentzer WC, Kalinyak KA, Sullivan KM, Abboud MR. Bone marrow transplantation for sickle cell disease: the United States experience. Am J Pediatr Hematol Oncol 1994;16:22-6.
9. Vermylen C, Cornu G. Bone marrow transplantation for sickle cell disease: the European experience. Am J Pediatr Hematol Oncol 1994;16:18-21.
10. Reutler E, Sullivan KM. Bone marrow transplantation for sickle cell disease. In: Forman SJ, Blume KG, Thomas ED, eds. Bone marrow transplantation. Boston: Blackwell Scientific, 1994:840-8.
11. Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993;329:840-4.
12. Platt O. The sickle syndromes. In: Handin RI, Lux SE, Stossel TP, eds. Blood: principles & practice of hematology. Philadelphia: J.B. Lippincott, 1995;1645-700.
13. Hopkins KA. Basic microlymphocytotoxicity test. In: Zachary AA, Teresi GA, eds. Laboratory manual. 2nd ed. Lenexa, Kans.: American Society for Histocompatibility and Immunogenetics, 1990;195-201.
14. Walters MC., Sullivan KM, Bernaudin F, et al. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood 1995;85:879-84.
15. Powars D, Weidman JA, Odom-Maryon T, Niland JC, Johnson C. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore) 1988;67:66-76.
16. Powars DR, Elliott-Mills DD, Chan L, et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann Intern Med 1991;115:614-20.
17. Dyer MJS, Hale G, Hayhoe FGJ, Waldman H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989;73:1431-9.
18. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314:729-35.
19. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993;329:1225-30.
20. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986;314:1006-10.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
22. Kalbfleisch JD, Prentice NL. The statistical analysis of failure time data. New York: John Wiley, 1980:79-81, 168-71.
23. Fisher LD, van Belle G. Biostatistics: a methodology for health sciences. New York: John Wiley, 1993:185-6.
24. Andreani M, Manna M, Lucarelli G, et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996;87:3494-9.
25. van den Bos C, Kieboom D, Wagemaker G, Correction of murine β-thalassemia by partial bone marrow chimerism: selective advantage of normal erythropoiesis. Bone Marrow Transplant 1993;12:9-13.
26. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995;16:31-42.
27. Schuening F, Deeg HJ, Bean MA, Storb R. Prevention of graft failure in patients with aplastic anemia. Bone Marrow Transplant 1993;12:Suppl 3:S48-S49.
28. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989;320:197-204.
29. Anasetti C, Doney KC, Storb R, et al. Marrow transplantation for severe aplastic anemia: long-term outcome in fifty "untransfused" patients. Ann Intern Med 1986;104:461-6.
30. Andreani M, Manna M, Nesci S, Fattorini P, Graziosi G, Lucarelli G. Persistence of mixed chimerism in class 3 thalassemic patients following BMT. Bone Marrow Transplant 1991;7:Suppl 2:75.
31. Bernaudin F, Souillet G, Vannier JP, et al. Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): the French experience. Bone Marrow Transplant 1993;12:Suppl 1:118-21.
32. Ferster A, Corazza F, Bujan W, et al. Patients with sickle cell anemia who present graft failure after bone marrow transplantation may develop increased levels of fetal hemoglobin associated with improved clinical presentation. In: Beuzard Y, Lubin B, Rosa J, eds. Sickle cell disease and thalassaemias: new trends in therapy, London: John Libbey, 1995:579-80.
33. Giardini C, Galimberti M, Lucarelli G, et al. Bone marrow transplantation in sickle-cell anemia in Peasaro. Bone Marrow Transplant 1991;7: Suppl 2:122-3.
34. Nesci S, Manna M, Andreani M, Fattorini P, Graziosi G, Lucarelli G. Mixed chimerism in thalassemic patients after hone marrow transplantation. Bone Marrow Transplant 1992;10:143-6.
35. Kapelushnik J, Or R, Filon D, et al. Analysis of β-globin mutations shows stable mixed chimerism in patients with thalassemia after bone marrow transplantation. Blood 1995;86:3241-6.
36. Walters MC, Patience M, Leisenring W, et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant (in press).
37. Piomelli S. Sickle cell diseases in the 1990s: the need for active and preventive intervention. Scmin Hematol 1991;28:227-32.
38. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332: 1317-22.
39. Styles LA, Vichinsky E. Effects of a long-term transfusion regimen on sickle cell-related illnesses. J Pediatr 1994;125:909-11.